We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

March 19, 2021

Safeguarding digital health solutions and successful IP strategies

Commentary
Kate O'Reilly
&

To many, digital health is a relatively novel industry that has emerged at the hazy pharma-tech interface. However, as its boundaries and benefits become more apparent, investment and regulatory activity are becoming increasingly supportive, and in favour of its evolution. Unsurprisingly, these ratifications combined with the fast evolving nature of digital health and its ambition to set itself apart, has set precedence for aggressive competition within the industry. Navigating regulatory pathways and establishing reimbursement routes are hot topics among industry leaders with regard to ensuring speed-to-market and broad user reach. But we rarely hear them discuss the importance of protecting the novelty of these innovations. Is diverted focus one of the reasons why we are beginning to witness a burgeoning medtech rivalry ?

The year 2020 alone saw a number of IP-based legal battles including the long-awaited eruption between telehealth giants Teladoc and Amwell. Last autumn Teladoc filed a lawsuit against its competitor Amwell on the back of a patent infringement accusation. Teladoc claimed that Amwells products including some of its telehealth carts, a digital scope and stethoscope infringed on patents that it acquired following the acquisition of InTouch Health earlier in the year. In response, Teladoc began seeking unspecified monetary and injunctive relief under patent law. The year came to a close marked by contention between Apple and AliveCor. A lawsuit filed by AliveCor detailed that the tools included in the Apple Watch Series 4 and later devices infringed on three patents held by AliveCor, all of which focus on cardiac arrhythmia. A year prior to the unveiling of the Apple Watch's ECG, AliveCor had launched an Apple Watch strap with a built-in ECG sensor called the KardiaBand but ended sales to focus on its six-lead smartphone ECG screening device.

The evidence is rife; digital health is one of those industries destined for IP rivalry. Experts in the industry report that medical device litigation is probably the most contentious with competitor litigations going more frequently to trial than in many other industries. The solution to this is undeniable. IP protection should assume a critical component of a company’s overarching digital health strategy. But how is IP protection in digital health achieved? 

Digital health solutions can be protected from IP theft by one or more of several ways depending on the individual component of interest i.e hardware, software, associated data analytics. The channels of IP that may be used to grant such protection are myriad and include:


Trademarks and design

A carefully selected and preserved trademark is a valuable asset for digital health innovators protecting against the registration of confusingly similar marks. Engaging with an IP attorney early on is imperative to ensuring the smooth sailing of solution naming and clearance. While trademark protection is a crucial part of a company’s underlying IP strategy, it is important to remember that while it protects the name, it does not prevent competitors from copying the function of a medical device. Design rights are another important consideration that impart protection against aspects of a product's appearance; factors which are often definitive to consumer uptake and HCP adoption.


Trade Secrets

Including details such as algorithms, or manufacturing secrets in standard operating procedures (SOPs), or marketing materials can inadvertently put companies at risk of IP theft. However, trade secret protection can be achieved by educating employees on keeping information confidential and implementing programs to preserve innovation seclusion. Trade secret law often appeals more to companies as courts in general are more willing to issue injunctions under trade secret litigation in comparison to the more complex patent litigation. 


Patents

Components of digital health that may be patentable include mechanical, chemical and electrical, as well as associated methods and protocols. Protection can also be sought for user interfaces by means of utility or design patent applications. Pretty straight forward, right? But for computer-based elements, and abstract ideas things get a little bit murky. Case law developments have made it difficult for software or technology built on abstract ideas to get patent protection, and most jurisdictions require that these components can demonstrate real life outcomes. reSET®, the first FDA-approved software-only prescription digital therapeutic is one example where patent protection options wane. The software-based CBT product for substance use disorder which established efficacy in a 12-week clinical trial lists several trademarks but has no associated patents or patent applications. 


Obtaining a patent can be a long and expensive process. In the US the process involves submitting a patent application to the US Patent and Trademark Office (USPTO). Preparing the submission can take anywhere in and around the 4-8 week mark. Not so bad eh? But after the application is filed, it can take an average of 2-3 years for examination prior to the issuance of an enforceable patent. Nevertheless, patents confer several advantages for inventors in that they offer the strongest form of IP protection and allow a monopoly over an invention for a fixed period. They are often considered currency to secure financing through venture capital or private equity investments. In addition to discouraging competitors and attracting investments, patents also bolster a company’s reputation for originality in its field, which helps attract top talent. 


The top 100 Global Digital Health Patents for 2018-2020 illustrated that patenting is the still one of the most sought after channels for protecting innovation. China's Ping An topped the IP charts leading with 1,074 patent patent filings during the time period, followed closely in line by Philips (1,021 applications) and Johnson & Johnson (535 applications). So far this year we have seen continued patent activity with Voluntis receiving a patent for its intelligent insulin titration support as part of its Theraxium Digital Therapeutic Platform, and Neurosigma expanding its patent portfolio to covering the use of trigeminal nerve stimulation (TNS) in the treatment of neurological and neuropsychiatric disorders. Mydecine also made headlines last month when it filed a provisional patent for its technology combining a digital mental health programme and the world’s first telehealth platform for psychedelic integration.

Product life cycle opportunities

One reason why companies initially lean towards digital solutions is to reinforce their IP portfolios and product commercialisation strategies. Patents for pharmaceutical drugs typically confer 20 years protection but once a patent expires and generics begin to hit the market it is estimated that sales of the originator drops by a whopping 80 percent. Prior to the digital revolution, drug product developments and iterations typically involved tweaks in formulations, routes of administration, expansion of indications or development of drug-drug combinations. The inception of the digital health era  has, however, created myriad opportunities to strengthen and diversify a drug patent portfolio by means of combination product approaches, or device differentiation. One example of this is the teaming up of Otsuka and Proteus to develop Abilify MyCite®. The prescription digital medicine combines the blockbuster antipsychotic Abilify® and embedded microsensors for digitally tracking drug ingestion and has shown to improve clinical outcomes compared to Abilify® creating a novel opportunity for extending the product life cycle.

Proteus’s patents covering innovations in Abilify MyCite® expire after those of Otsuka’s for Abilify®. 


In the US, patent extension is classified under FDA (505-B) and provides pharma an opportunity and incentive for iterative product development. The Otsuka and Proteus partnership is testament to the fact that combining digital health solutions with conventional drugs can be leveraged to extend patent lifespans, allowing greater return on investment and invigorated product life cycles.


………... but what about all that data?

It goes without saying that digital health products collect an abundance of data, typically stored in designated databases. While the data itself may not be protected by copyright, the database or data collection may be protected if it is considered sufficiently avant-garde.


Building a successful digital health IP Strategy 

IP is a key driver of innovation in the digital health industry and investing in its protection will reap enormous reward and diversity of solutions in the future. One crucial consideration to bear in mind is that product life cycles in the digital health industry are typically much shorter than other healthcare industries, putting added pressure on digital health manufacturers to regularly revise and update their IP strategy. Furthermore, considering the patentable exclusion criteria which pertains to the likes of mathematical methods and algorithms, players in the digital health field rely more heavily on streams of auxiliary protection such as copyright and trade secrets.


IP has facilitated cutting-edge collaborations between the medtech, healthcare and pharmaceutical industries and nurturing an ecosystem that appropriately balances innovation with IP challenges is imperative to ensuring continued industry growth and timely access by patients to innovative healthcare solutions worldwide. Every single solution on the digital health market today is a by-product of some individual's incipient idea. How would you protect the transformation of your own ideas into assets?


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx

16th August @ 10:45AM EDT

It is one of the key questions that every digital therapeutic (DTx) company must answer - what business model will set them up for success in the long run? Join this meeting to discuss this further and share your experiences with your peers working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Payers Partnerships for DTx

17th August @ 10:45AM EDT

Digital Therapeutics (DTx) vendors face many challenges on their journey to commercialization, such as generating clinical data, health economics evidence and achieving regulatory status. Join this meeting to discuss this topic further and share your experiences with others working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sprint: How to Overcome the Blockers to DTx Adoption and Measure Success? (Part 2)

25th August @ 10:45AM EDT

While new legislations and rules (such as DiGA in Germany) have opened new options for reimbursement, adoption of digital therapeutics (DTx) remains insufficient to achieve the revenue expected from these solutions. Join this 2 part sprint to discuss this topic further.

Featuring
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee
Richard DeNunzio
Richard DeNunzio
SVP, Commercial at Click Therapeutics, Inc.
Featuring
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee
Richard DeNunzio
Richard DeNunzio
SVP, Commercial at Click Therapeutics, Inc.
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: DTx Reimbursement in the US: Government-sponsored plans (Medicaid and Medicare)

30th August @ 10:45AM EDT

Are you a digital therapeutics (DTx) company seeking reimbursement in the US market? Join this masterclass led by the biopharma and DTx reimbursement expert Mike Pace to dive deeper into this topic.

Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Executive 1-2-1 with the HealthXL Digital Health Community

15th August @11AM EDT

Do you want to network with other innovators and leaders in digital health? Are you looking to identify potential partners? Join us for the new HealthXL style of virtual speed networking and meet other members working in this space!

Featuring
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Chris Wasden
Chris Wasden
Head of Pharma Speciality Solutions & Corporate Strategy, Twill
Featuring
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Chris Wasden
Chris Wasden
Head of Pharma Speciality Solutions & Corporate Strategy, Twill
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx

16th August @ 10:45AM EDT

It is one of the key questions that every digital therapeutic (DTx) company must answer - what business model will set them up for success in the long run? Join this meeting to discuss this further and share your experiences with your peers working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Payers Partnerships for DTx

17th August @ 10:45AM EDT

Digital Therapeutics (DTx) vendors face many challenges on their journey to commercialization, such as generating clinical data, health economics evidence and achieving regulatory status. Join this meeting to discuss this topic further and share your experiences with others working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems
Digital Health in Oncology
Digital Health in Oncology
Digital Health in Oncology
Digital Health in Oncology

Incentive Models for HCP & Care Team to Adopt Digital Health in Oncology

23rd August @ 10:45AM EDT

What are the best incentive models to encourage health care professionals (HCPs) and care teams to adopt digital health in oncology? Join this meeting to discuss this topic further with others working in this space.

Featuring
Susan Bratton
Susan Bratton
CEO & Founder at Savor Health
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche
Featuring
Susan Bratton
Susan Bratton
CEO & Founder at Savor Health
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.